Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | GFER | P55789 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.61 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.60 |
| ▸ | TCF4 | P15884 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10492241 | 0.87 | AKR1B1 (0.85) | MEN1KMT2AGFERMAPK1NPC1 | |
| SCHEMBL10492234 | 0.87 | AKR1B1 (0.85) | MEN1KMT2AGFERMAPK1NPC1 | |
| SCHEMBL29408619 | 0.86 | MEN1 (0.72) | MEN1KMT2AGFERMAPK1NPC1 | |
| SCHEMBL19736093 | 0.86 | MEN1 (0.72) | MEN1KMT2AGFERMAPK1NPC1 | |
| SCHEMBL19736167 | 0.84 | MEN1 (0.68) | MEN1KMT2AAKR1B1PTPN1POLB | |
| SCHEMBL29408637 | 0.84 | MEN1 (0.68) | MEN1KMT2AAKR1B1PTPN1POLB | |
| SCHEMBL6720212 | 0.83 | CTNNB1 (0.72) | MEN1KMT2AGFERMAPK1NPC1 | |
| SCHEMBL18102986 | 0.82 | AKR1B1 (0.87) | MEN1KMT2AGFERMAPK1NPC1 | |
| SCHEMBL18102842 | 0.82 | AKR1B1 (0.87) | MEN1KMT2AGFERMAPK1NPC1 | |
| SCHEMBL5218108 | 0.81 | ADAMTS5 (0.84) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | TYMP, IMPDH1, SAMHD1 | MEN1 4601/4885KMT2A 1477/4885GFER 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.